



This is a repository copy of *ASXL3-related disorder: molecular phenotyping and comprehensive review providing insights into disease mechanism.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/209875/>

Version: Published Version

Article:

Woods, E. orcid.org/0000-0003-2349-2688, Holmes, N., Albaba, S. et al. (2 more authors) (2024) ASXL3-related disorder: molecular phenotyping and comprehensive review providing insights into disease mechanism. *Clinical Genetics*, 105 (5). pp. 470-487. ISSN 0009-9163

<https://doi.org/10.1111/cge.14506>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

REVIEW



WILEY

ASXL3-related disorder: Molecular phenotyping and comprehensive review providing insights into disease mechanism

Emily Woods^{1,2} | Nicola Holmes³ | Shadi Albaba³ | Iwan R. Evans^{2,4} |
Meena Balasubramanian^{1,2,4}

¹Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, UK

²Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK

³Sheffield Diagnostic Genetics Service, Sheffield Children's Hospital, Sheffield, UK

⁴The Bateson Centre, University of Sheffield, Sheffield, UK

Correspondence

Emily Woods and Meena Balasubramanian, Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, UK.
Email: meena.balasubramanian@nhs.net; m.balasubramanian@sheffield.ac.uk; emily.woods2@nhs.net

Abstract

ASXL3-related disorder, sometimes referred to as Bainbridge-Ropers syndrome, was first identified as a distinct neurodevelopmental disorder by Bainbridge et al. in 2013. Since then, there have been a number of case series and single case reports published worldwide. A comprehensive review of the literature was carried out. Abstracts were screened, relevant literature was analysed, and descriptions of common phenotypic features were quantified. ASXL3 variants were collated and categorised. Common phenotypic features comprised global developmental delay or intellectual disability (97%), feeding problems (76%), hypotonia (88%) and characteristic facial features (93%). The majority of genetic variants were de novo truncating variants in exon 11 or 12 of the ASXL3 gene. Several gaps in our knowledge of this disorder were identified, namely, underlying pathophysiology and disease mechanism, disease contribution of missense variants, relevance of variant location, prevalence and penetrance data. Clinical information is currently limited by patient numbers and lack of longitudinal data, which this review aims to address.

KEYWORDS

ASXL3, Bainbridge-Ropers syndrome, *Drosophila melanogaster*, neurodevelopmental disorder

1 | INTRODUCTION

ASXL3-related disorder, also known as Bainbridge-Ropers syndrome, is a neurodevelopmental disorder that was first described by Bainbridge et al.¹ It is associated with heterozygous pathogenic variants in the ASXL3 gene, located at 18q12.1 (OMIM *615115). It is associated with a non-specific neurodevelopmental phenotype; a diagnostic clinical criterion has not been established.² Diagnosis is confirmed by the identification of a pathogenic, or likely pathogenic, variant in ASXL3, as per the American College of Medical Genetics (ACMG) diagnostic standards and guidelines for interpretation of variants.^{3,4}

The Additional Sex Combs-Like (ASXL) gene family comprises ASXL1, ASXL2 and ASXL3. Germline pathogenic variants in ASXL1 cause Bohring-Opitz syndrome, a neurodevelopmental disorder characterised by feeding difficulties, eye abnormalities (exophthalmos, strabismus), dysmorphism, hypertrichosis, specific body posture and microcephaly.⁵ Germline pathogenic variants in ASXL2 cause Shashi-Pena syndrome, which is associated with a highly variable neurodevelopmental phenotype, dysmorphism, macrocephaly, hypotonia and more rarely, bone and heart abnormalities.⁶

ASXL3-related disorder is a Chromatin Modifying Disorder. The ASXL genes code for proteins that are involved in epigenetic mechanisms and transcriptional regulation, and are therefore implicated in

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Authors. *Clinical Genetics* published by John Wiley & Sons Ltd.

embryogenesis.^{7,8} Functional studies with fibroblasts have elucidated that truncating *ASXL3* variants cause disruption in histone H2A (H2AK119Ub1) deubiquitination and therefore, have a role in transcriptional regulation and chromatin remodelling.⁹ These are relevant to developmental and proliferative molecular processes, which suggests a role in the pathophysiology of atypical neurodevelopment.⁹ However, a defined pathophysiological process of disease has not yet been identified, and further functional work is required.

Through large-scale whole exome sequencing research projects,^{10,11} and the subsequent expansion of first-line Whole Genome Sequencing, increasing numbers of individuals are being identified to have genetic heterogeneity of genes such as *ASXL3*, as a cause of underlying developmental delay or intellectual disability. Pathogenic variants in *ASXL3* are one of the 10 commonest single gene causes of developmental delay or intellectual disability, but these studies are predominantly based on people with Northwest European ancestry.^{10,12} Case report publications have since shown affected individuals from various ancestral backgrounds, which proves its relevance worldwide.^{13–19} However, the prevalence of *ASXL3*-related disorder has not yet been quantified. There is potential scope for interrogation of population-based data to bridge this gap in our knowledge.

This review summarises the current medical literature on *ASXL3*. It includes a comprehensive list of previously published variants, and a description of what is currently known of the clinical phenotypic spectrum.

2 | MOLECULAR SUMMARY

2.1 | Protein structure and function

Additional Sex Combs-Like (ASX) protein was initially discovered in *Drosophila melanogaster* as a member of the polycomb group of

proteins responsible for regulating *HOX* gene expression, which controls skeletal patterning during embryonic development.²⁰ While they are not essential for initiating homeotic gene repression, polycomb group proteins assume a critical function in maintaining repression as development advances. The human homologues of ASX were later identified as Additional Sex Combs-Like one, two and three (*ASXL1*, *ASXL2* and *ASXL3*).⁸

The *ASXL3* gene is the largest of the *ASXL* family and comprises 12 exons and encodes the *ASXL3* protein, made up of 2248 amino acids. *ASXL3* has ASXN, ASXH, ASXM1, ASXM2 and PHD conserved domains⁸ (Figure 1). It is highly expressed in the cerebral cortex, ovaries, testes and smooth muscle tissues.⁸

The N terminal ASXN domain, also referred to as HARE-HTH (HB1, ASXL and restriction endonuclease helix-turn-helix), is predicted to facilitate DNA binding.²⁵ This domain is notably absent from the *Drosophila* homologue.²⁶ The ASX homology (ASXH) domain, also known as the DEUBAD (deubiquitinase adaptor) domain, spans exons 9–11. ASXH plays a crucial role in engaging with epigenetic regulatory proteins, such as BRCA1 Associated Protein 1 (BAP1)²⁷ (Figure 2). The ASXM1 and ASXM2 domains serve as protein–protein interaction modules, facilitating the association of ASXL proteins with nuclear hormone receptors (NHRs) and their cofactors.⁷ The C terminal plant homeodomain (PHD) is a zinc finger domain which recognises chromatin histone post-translational modifications.²⁹ In contrast with other ASX proteins, *ASXL3* features a proline-rich region upstream of its PHD domain.⁸

Although the role of *ASXL3* is not fully understood, there is evidence of interaction with several proteins implicated in the regulation of transcription (Figure 3). Perhaps the most well-characterised, is the interaction of *ASXL3* with BAP1, in the formation of the polycomb repressive deubiquitination (PR-DUB) complex. BAP1 is a nuclear ubiquitin carboxy-terminal hydrolase that removes mono-ubiquitin from histone H2A lysine 119 (H2AK119Ub1), maintaining transcriptional




FIGURE 1 Predicted 3D structure and domains of the human *ASXL3* protein. Original illustrations created with RCSB.org²¹ based on the computed structure model AF_AFQ9C0F0F1.^{21,22,23} The domains of *ASXL3* (UniProt: Q9C0F0) are highlighted based on positional information cited by Katoh²⁴: ASXN (red), ASXH (blue), ASXM1 (purple), ASXM2 (green) and PHD (orange). Note that the global per residue confidence score (pLDDT) in this predicted model is very low (39.71). [Colour figure can be viewed at wileyonlinelibrary.com]




FIGURE 2 Original illustrations created with RCSB.org²¹ based on the computed structure model MA_MAT3VR3881²⁸ showing the predicted interaction between BAP1 (residue 1–699) and ASXL3 (residue 248–348). The ASXH domain of ASXL3 (UniProt: Q9CF0F; blue) is predicted to interact with the ULD domain of BAP1 (UniProt: Q92560; pink) via hydrogen bonds at the following ASXL3 residues: Ser274, Leu286, Val290, Asp291, Ser305, Trp319 and Arg322. Note that the global per residue confidence score (pLDDT) in this predicted model is low (81.747). [Colour figure can be viewed at wileyonlinelibrary.com]

repression.²⁷ The PR-DUB complex is primarily associated with gene silencing, but Kolovos et al.³¹ found that ASXL proteins, via their interaction with BAP1, facilitate gene activation associated with cell metabolism and homeostasis.

Srivastava et al.⁹ reported that fibroblasts from individuals with a pathogenic ASXL3 variant had a significant increase in H2AK119Ub1, supporting the role of ASXL3 in PR-DUB mediated deubiquitination. Furthermore, they observed differential expression of more than 500 genes in patient fibroblasts relative to controls, with a particular bias towards genes involved in transcriptional regulation, development and proliferation. Structural, biochemical and functional studies of human PR-DUB indicate that ASXL proteins are responsible for the activation of BAP1.³² The association of the ULD (ubiquitin C-terminal hydrolase L5-like domain) of BAP1 and the ASXH domain of ASXL proteins has been shown to increase the affinity of PR-DUB for ubiquitin.^{27,33,34}

Szczepanski et al.³⁵ reported that ASXL3 interacts with BRD4 (bromodomain-containing protein 4), a protein which promotes transcription and elongation by binding directly to acetylated histones at enhancers and promoters.³⁶ ASXL3 appears to function as an adaptor protein which forms a bridge between BRD4 and BAP1, maintaining chromatin occupancy of this complex to active enhancers, thus sustaining transcriptional activation.³⁵

3 | METHODS

3.1 | Literature search

A simultaneous literature search was performed on PubMed database. The initial search using keyword ‘ASXL3’ comprised 89 articles, and a filtering process yielded 54 results (Figure S1). A second similar search




FIGURE 3 Original illustration created at STRING-db.org³⁰ depicting the interactions of the human ASXL3 protein which are predicted with medium confidence (>0.4) based on textmining, experiments, databases, co-expression, neighbourhood, gene fusion and co-occurrence evidence. In descending order of confidence, putative polycomb group protein ASXL3 is predicted to interact with ubiquitin carboxyl-terminal hydrolase BAP1, histone-lysine N-methyltransferase EZH2, putative polycomb group protein ASXL2, bromodomain-containing protein 4 (BRD4), polycomb group protein ASXL1, E3 ubiquitin-protein ligase RING2 (RNF2), zinc finger protein 292 (ZNF292), polycomb protein SUZ12, transcriptional repressor protein YY1 and E3 ubiquitin-protein ligase RING1. [Colour figure can be viewed at wileyonlinelibrary.com]

with keywords 'Bainbridge-Ropers Syndrome' yielded 32 results. Duplicate and corrigendum articles were removed, and remaining articles were screened for relevance.

3.2 | Study types

There were 11 case series published in the literature; the largest was a cohort of 45 individuals. There were 18 individual case reports describing relevant individuals internationally, including individuals from the United Kingdom, China, Japan, Korea, Sudan, Mexico and America with a variety of ancestral backgrounds. The total number of probands described in the literature with apparent heterozygous pathogenic, or likely pathogenic, ASXL3 variants was 108. Information was provided for 101/108 of these variants; the exception being seven individuals described by Ikekwere et al.³⁷ (assuming they were not a duplicated cohort). The majority of individual case reports described paediatric patients.

3.3 | Information screening, extraction and construction

A table of genetic variants was compiled including details of variant location, pathogenicity and predicted effect (Table A1 in Appendix). Cases submitted to DECIPHER database (<https://www.deciphergenomics.org/>) had their unique DECIPHER identifier number recorded.

4 | RESULTS

4.1 | Clinical features

The initial clinical phenotype described by Bainbridge et al.¹ comprised four individuals with developmental delay, feeding difficulties, neurological abnormalities and failure to thrive. With the identification and publication of more individuals, the phenotypic spectrum has expanded to include hypotonia (88%), characteristic facial features (93%), palate abnormalities (61%), musculoskeletal features (66%), behavioural issues (77%), strabismus (58%), sleep disturbance (53%) and autistic features (65%). Intellectual disability (or its precursor, global developmental delay) was almost universal, at 97% prevalence. A summary of the commonly described phenotypic features in the literature is summarised in Table 1.

4.2 | Common clinical features

4.2.1 | Developmental delay

A description of developmental delay and intellectual disability ranged from mild to profound. The majority had speech and language delay as a component of this. Some individuals have been described to have language regression in childhood, and some have been described to communicate by alternate methods, such as Makaton signing.

4.2.2 | Autistic traits and behavioural difficulties

Autistic traits included obsessions, inflexibility and incapacity for change, stereotypies such as hand-flapping and rocking, and difficulties with sensory processing. Other behavioural difficulties included self-injurious behaviours, aggression towards caregivers, emotional dysregulation with outbursts of either laughter, screaming, aggression and bruxism.

4.2.3 | Musculoskeletal

Many individuals had hypotonia, which may have explained the accounts of hypermobility. Other musculoskeletal features were accounted for by spine and thoracic-wall abnormalities (scoliosis, kyphosis, pectus excavatum), digit and joint abnormalities (contractures, arachnodactyly, ulnar deviation, camptodactyly, overlapping digits) and foot abnormalities (pes planus, narrow feet, varus deformity). A severe multi-joint phenotype of arthrogyrosis multiplex congenita has been described in patients with pathogenic ASXL3 variants.⁵²

4.2.4 | Connective tissue features

There were reports of long slender hands and digits, and Marfanoid body habitus. Palate abnormalities were described in 61% of individuals; these were most often high and narrow palate. There was one description of a submucous cleft⁴⁵ and one patient with a cleft palate.⁵¹ Despite the overlapping Marfanoid features, there have been no reports of children with a dilated aorta, as is associated with Marfan syndrome and other connective tissue disorders. One child was found to have a subclavian artery aneurysm.⁵³

4.2.5 | Feeding

Several individuals with feeding difficulties presented with failure-to-thrive in infancy. Some babies required naso-gastric tube (NGT) insertion. There were reports of ongoing requirement for enteral feeding in childhood and need for percutaneous gastrostomy feeding. Some feeding difficulties in infancy were reported to improve with time.

4.2.6 | Dysmorphic features

Non-specific dysmorphism has been described, with no pathognomonic or defining facial phenotype, but a clear disposition for certain features. Common features included abnormal head shape (microcephaly, dolichocephaly), prominent forehead, highly arched eyebrows, synophrys, widely spaced and deep-set eyes, down-slanting palpebral fissures, long and tubular nose, low-hanging columella, prominent nasal bridge, wide mouth, high arched palate, everted vermilion of the lower lip, micrognathia and crowded teeth, but these may not be recognised until after diagnosis.² Additional dental

TABLE 1 A summary of the clinical phenotype of individuals with ASXL3-related disorder in the literature.

Paper	Feeding difficulties	Hypotonia	Characteristic facial features	Down-slanting palpebral fissures	Palate abnormality	Speech delay/absent speech	Global delay/Intellectual disability	Behavioural issues	Seizure	Musculoskeletal features	Strabismus	Sleep disturbance	Autism diagnosis/autistic traits
Schirwani et al. ³⁸ <i>n</i> = 45	28/40	33/40	31/31	21/33	21/30	43/43	29/29	29/36	11/39	27/35	Unknown	Unknown	Unknown
Balasubramanian et al. ³⁹ <i>n</i> = 12	9/12	12/12	9/12	6/12	9/12	12/12	12/12	9/12	3/12	7/12	7/12	2/12	9/12
Wang et al. ¹⁷ <i>n</i> = 1	1/1	1/1	1/1	0/1	0/1	1/1	1/1	0/1	0/1	1/1	0/1	1/1	0/1
Wu and Cong ¹⁸ <i>n</i> = 1	1/1	1/1	1/1	Unknown	1/1	1/1	1/1	1/1	0/1	0/1	1/1	Unknown	1/1
Srivastava et al. ⁹ <i>n</i> = 3	3/3	3/3	2/3	2/3	Unknown	3/3	2/3	1/1	1/3	1/2	Unknown	Unknown	Unknown
Dad et al. ⁴⁰ <i>n</i> = 1	0/1	0/1	1/1	1/1	Unknown	1/1	1/1	Unknown	0/1	Unknown	Unknown	1/1	1/1
Qiao et al. ⁴¹ <i>n</i> = 1	1/1	1/1	1/1	0/1	1/1	Unknown	Unknown	Unknown	0/1	1/1	Unknown	1/1	Unknown
Li et al. ⁴² <i>n</i> = 1	1/1	1/1	1/1	1/1	0/1	1/1	1/1	1/1	0/1	0/1	1/1	Unknown	1/1
Yang et al. ¹⁹ <i>n</i> = 1	1/1	1/1	1/1	0/1	0/1	Unknown	1/1	Unknown	0/1	1/1	1/1	Unknown	Unknown
Cuddapah et al. ⁴³ <i>n</i> = 4	4/4	4/4	2/4	1/4	1/4	3/3	4/4	3/4	Unknown	0/4	1/4	1/4	3/4
Bainbridge et al. ¹ <i>n</i> = 4	3/4	4/4	4/4	3/3	1/1	3/3	4/4	Unknown	Unknown	3/4	Unknown	Unknown	Unknown
Koboldt et al. ⁴⁴ <i>n</i> = 2	2/2	2/2	2/2	2/2	2/2	2/2	2/2	2/2	2/2	Unknown	Unknown	Unknown	2/2
Kuechler et al. ⁴⁵ <i>n</i> = 6	6/6	6/6	6/6	6/6	5/6	6/6	6/6	Unknown	2/6	6/6	5/6	2/2	Unknown
Chinen et al. ¹³ <i>n</i> = 1	0/1	1/1	1/1	0/1	0/1	1/1	1/1	1/1	0/1	1/1	0/1	0/1	0/1
Contreras-Capetillo et al. ¹⁴ <i>n</i> = 1	1/1	1/1	1/1	0/1	1/1	1/1	1/1	Unknown	1/1	0/1	0/1	Unknown	Unknown
Dinwiddie et al. ¹⁵ <i>n</i> = 1	1/1	1/1	1/1	0/1	0/1	1/1	1/1	1/1	0/1	1/1	0/1	1/1	1/1
Wayhelova et al. ⁴⁶ <i>n</i> = 1	1/1	1/1	1/1	0/1	1/1	1/1	1/1	Unknown	Unknown	0/1	1/1	Unknown	1/1
Khan et al. ⁴⁷ <i>n</i> = 1	1/1	1/1	Unknown	Unknown	1/1	Unknown	1/1	Unknown	1/1	1/1	Unknown	1/1	1/1
Myers et al. ⁴⁸ <i>n</i> = 3	1/3	1/3	Unknown	Unknown	Unknown	1/1	3/3	Unknown	3/3	1/1	Unknown	Unknown	0/1
Yu et al. ⁴⁹ <i>n</i> = 3	1/4	4/4	4/4	1/4	0/2	4/4	4/4	Unknown	0/4	1/4	Unknown	1/4	1/4

(Continues)

TABLE 1 (Continued)

Paper	Feeding difficulties	Hypotonia	Characteristic facial features	Down-slanting palpebral fissures	Palate abnormality	Speech delay/absent speech	Global delay/intellectual disability	Behavioural issues	Seizure	Musculoskeletal features	Strabismus	Sleep disturbance	Autism diagnosis/autistic traits
Hori et al. ¹⁶ n = 1	1/1	0/1	1/1	1/1	Unknown	1/1	1/1	1/1	0/1	1/1	1/1	1/1	1/1
Bacrot et al. ⁵⁰ n = 1	N/A	N/A	1/1	0/1	1/1	N/A	N/A	N/A	N/A	1/1	N/A	N/A	N/A
Schirwani et al. ⁵¹ n = 5	5/5	5/5	5/5	4/5	3/5	5/5	4/5	3/5	1/5	2/5	3/5	4/5	3/4
Ikekwe et al. ³⁷ n = 7	Unknown	Unknown	Unknown	2/7	1/7	2/7	6/7	4/7	3/7	Unknown	Unknown	5/6	3/7
Total	72/95 = 76%	84/95 = 88%	77/83 = 93%	51/90 = 57%	49/80 = 61%	93/98 = 95%	87/90 = 97%	56/73 = 77%	28/92 = 30%	56/85 = 66%	21/36 = 58%	21/40 = 53%	28/43 = 65%

Note: Percentages are rounded to the nearest whole number. 'Unknown' means there was no mention of this feature in the clinical description, or that clinical description was insufficient to infer otherwise. 'N/A' means not applicable, in the case of foetal death. Denominators may vary per study due to the inclusion only of individuals described in sufficient detail to infer if feature is present or not.

abnormalities have also been reported, including large teeth, missing dentition and enamel hypoplasia.⁴²

4.2.7 | Sleep abnormalities

Sleep disturbance included reports of obstructive sleep apnoea, poor sleep and easy waking. A report of hyperventilation athetosis was reportedly associated with the sleep-wake cycle, immediately prior to falling asleep.⁴⁰

4.2.8 | Brain abnormalities

Structural brain abnormalities have been described, but are not as easily quantified, as MRI brain imaging is not always carried out unless there is a clinical indication.

Normal brain imaging was reported in most individuals, however there were some non-specific abnormalities such as white-matter loss.^{1,9,13,38,45} One individual was reported to have normal early MRI scans but saw a clinical decline in correlation with subsequent cerebral and cerebellar atrophic changes.⁴⁷ Cerebellar vermis hypoplasia has been described in some individuals.^{1,9,45} There has been one reported case of pontocerebellar hypoplasia, a severe and progressive neurodegenerative disorder, which resulted in foetal termination.⁵⁰ Prominence of the sylvian fissure has been described in two individuals,^{13,49} ventricular dilatation in three individuals,^{18,38,45} and thinning of the corpus callosum in eight individuals.^{9,13,38,44,45} Other abnormalities described included abnormal brainstem and decreased myelination.^{1,38}

4.2.9 | Seizures and EEG phenotype

A variety of seizure types have been reported, including generalised (tonic-clonic and absence), focal and complex focal seizures. Variations of focal seizures have been described including atonic seizures (associated with other behaviours such as head-bobbing or spontaneous outbursts of laughter), myotonic seizures (with partial-body stiffness or shaking) and subclinical seizures.^{43,47} A typical epilepsy phenotype was described consisting of generalised epilepsy that starts in childhood, with absence seizures and tonic-clonic seizures.⁴⁸ However, there have been reports of later-onset epilepsy starting during adulthood.⁴⁷ Seizure frequency has been variably reported, with some individuals having sporadic and self-limiting epilepsy, some that resolved with treatment, and some individuals having up to 140 seizures a day with intractable treatment resistant epilepsy.^{47,48}

Electroencephalogram (EEG) testing has been variably reported, with some children having normal EEGs, and some having severely abnormal EEGs. Abnormal EEG reports included multifocal epileptiform activity including sharp-waves, variable background slowing, posterior rhythmic delta activity, diffusely increased beta waves.^{38,47,48} No consistent recognisable EEG pattern has been currently identified.




FIGURE 4 Original illustration detailing location of previously published pathogenic, or likely pathogenic, heterozygous variants in exons 10, 11 and 12. [Colour figure can be viewed at wileyonlinelibrary.com]

Different treatments for epilepsy have been tried with variable success including valproate, clobazam, ethosuximide, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenobarbital, topiramate, lacosamide, eslicarbazepine, brivaracetam and perampnel. One patient with a severe phenotype was on oxcarbazepine, rufinamide, clobazam and cannabidiol, after previously unsuccessful treatments with zonisamide, clonazepam, topiramate, lacosamide and valproic acid.⁴⁷ Consideration of vagal nerve stimulator (VNS), ketogenic diet or focal resection has been suggested for patients with intractable medication-resistant epilepsy. One individual described by Schirwani et al.⁵³ was non-responsive to VNS insertion.

5 | VARIANTS

5.1 | Location of variants

The location of ASXL3 variants have been primarily identified within exon 11 and exon 12, which may be in keeping with their large size at 83% of the total ASXL3 gene coding sequence (Figure 4). However, as represented in Figure 4, there is propensity for variant clustering within these two exons. There have been two de novo splice-site variants published.^{16,48} There has been one publication of a variant in exon 3 (c.187C>T p.(Arg63*)),³⁸ There have been three published variants in exon 10 (c.1074T>A p.(Tyr358*), c.1082dup p.(Leu362fs), c.1063G>T p.(Glu355*)).^{17,39} An individual with an intragenic deletion at 18q12.1 spanning exons 2–8 was also described by Schirwani et al.³⁸ Intragenic deletions have not been described elsewhere, but the loss-of-function mechanism fits with what is seen in the eligible variants.

Some variants have been reported in more than one individual. The clinical details and DECIPHER identifying numbers were compared to ensure these were not duplicate reports of the same individual. Variant c.3106C>T p.(Arg1036*) has been reported five times^{38,44,45,48}; c.4330C>T p.(Arg1444*) has been reported five times^{9,38,39}; c.4399C>T p.(Arg1467*) has been reported four times^{38,49}; c.4534C>T p.(Gln1512*) and c.1534_1535del p.(Leu512fs) have both been reported twice³⁸; c.3464C>A p.(Ser1155*) has been reported twice^{38,41}; c.1990C>T p.(Gln664*) has been reported twice.^{38,43}

Yu et al.⁴⁹ compared the clinical phenotypes of previously reported loss-of-function variants at the 5' mutational cluster region in exon 11 ($n = 15$), with the 3' mutational cluster region in exon 12 ($n = 20$) and did not demonstrate any statistically significant differences in phenotype. The only exception was the clinical feature of hypertelorism, which was more common in the 3' mutational cluster region.⁴⁹ Currently, there are insufficient patient numbers with the same variant to draw any meaningful conclusions about specific location genotype–phenotype correlations. The location of known mutational clusters are highlighted in Figure 5.

The majority of variants were described as de novo. The majority of these were confirmed by parental genetic testing. In a few individuals, inheritance was not genetically confirmed (Table A1 in Appendix). Individuals with variants c.4534C>T p.(Gln1512*) and c.2791_2792del p.(Gln931fs) were presumed to be inherited, as parents had a consistent ASXL3-related disorder phenotype.⁵³ There have been genetically confirmed inherited cases. Of these, a c.4441dup p.(Leu1481fs) variant was seen in a clinically severely affected daughter and clinically unaffected mother.⁵³ This intrafamilial heterogeneity poses the possibility of either a very mild, or asymptomatic phenotype, or elucidates the possibility of reduced penetrance.




FIGURE 5 Original illustration showing the position of ASXL3 exons, domains, and codons, highlighting the location of 5' and 3' mutational cluster regions. [Colour figure can be viewed at wileyonlinelibrary.com]

In order to help with the classification of variants of uncertain clinical significance and to understand the role of epigenetics, one study has looked for a methylation signature for ASXL disorders, but did not elucidate a methylation signature for ASXL3-related disorder.⁵⁵ However, this was the first published study of this nature, and was limited to three ASXL3 variants.

5.2 | Missense variants

Missense variants in ASXL3 have been associated with Autism Spectrum Disorder without the additional phenotype of developmental delay and dysmorphism, as seen in ASXL3-related disorder.⁵⁶ An individual with homozygous c.3136G>A p.(Gly1046Arg) missense variant in exon 12 had developmental delay and seizures, this could be explained by an alternative confirmed genetic diagnosis, and so this ASXL3 variant was reported as likely benign.⁵⁷ However, the individual also had cortical atrophy, gastroesophageal reflux and microcephaly that may not have been attributable to this alternative diagnosis. A second individual with homozygous c.2471C>T p.(Pro824Leu) missense variant in exon 11 was reported as benign by Alfares et al.,⁵⁸ but this lacked detailed phenotyping. An additional individual with compound heterozygous missense variants c.2965C>G p.(Arg989Gly) and c.3078G>C p.(Lys1026Asn) had severe short stature and IGF1 deficiency, developmental delay and craniofacial abnormalities.⁵⁹ This was described as the first report of compound heterozygous variants causing a 'typical' ASXL3 phenotype and hypothesised a molecular interaction between ASXL3 and IGF1. However, the ASXL3 variants were not classified as pathogenic, and Schirwani et al.³⁸ later reported that an alternative diagnosis had been established.

Lack of functional assays for missense variants limits the use of further evidence for the assignment of pathogenic/likely pathogenic classification. Previously reported missense variants were classified as likely benign or variants of unknown clinical significance by Schirwani et al.³⁸ in accordance with the ACMG criteria.^{3,4} Missense constraint scores of 0.61 on gnomAD v2.1.1⁶⁰ and 1.08 on DECIPHER⁶¹ suggest that ASXL3 is fairly tolerant of missense variants, in contrast with its

intolerance to loss of function variants. This may be consistent with a possible recessive mode of inheritance for missense variants.

5.3 | Mosaic variants

A severely developmentally delayed individual with typical features of ASXL3-related disorder was found to have a mosaic c.1632_1637delins31 p.(Pro545Leufs) variant present at 35% level in saliva (but unknown Central Nervous System contribution).⁵¹ There is evidence that mosaicism in more than 20% of cells indicates an early embryonic event, and therefore a more likely clinically significant phenotype.⁶²

Two pairs of siblings have been reported with c.3284_3288del p.(Thr1096Asnfs) and c.4509_4513dup p.(Val1505Aspfs) variants, with assumed gonadal mosaicism in parents.⁵¹

5.4 | Genetic aetiology

The majority of variants are de novo truncating variants with a predicted loss-of-function (Table A1 in Appendix). Haploinsufficiency is a proven mechanism of pathogenicity, as a result of RNA mediated decay, truncated or null protein (Table A1 in Appendix). A dominant-negative effect was also proposed by Bainbridge et al.,¹ but there is evidence against this, whereby frog assays result in rescue of the ASXL3 knockdown phenotype by both full-length and truncated proteins.⁶³

Preliminary mouse studies have found that compound heterozygous ASXL3 variants show significantly reduced mRNA levels in the cerebrum and cerebellum compared to controls, which conforms with the neurodevelopmental phenotype.⁶⁴ In a study of *Xenopus laevis*, ASXL3 knockdown caused abnormal neuronal embryological development, which further elucidates the underlying mechanism of disease in early development.⁶³ However, this study presented some contradictory results with ectopic human ASXL3 protein.⁶³

Further molecular and functional work is required to further understand the genetic aetiology and disease mechanisms.

6 | DISCUSSION

6.1 | Description of literature

The current literature consists primarily of individual case reports. There are relatively few case series, the largest detailing 45 individuals. There is relatively little literature on the mechanisms of disease and functional studies.

There is literature on somatic *ASXL3* variants, its role in the oncogenic axis, and association with cancers. This is not relevant to *ASXL3*-related disorder, which describes germline *ASXL3* variants. There has been one report of cancer (precursor B-cell acute lymphoblastic leukaemia) in a child with *ASXL3*-related disorder.⁶⁵ Individuals with *ASXL3*-related disorder are not thought to be at any increased risk of cancers. Comparatively, somatic gene variants in *ASXL1* are associated with myeloid malignancies, and *ASXL1*-related disorder (Bohring-Opitz syndrome) is associated with an increased risk of Wilms tumour.⁵

Compound heterozygous *ASXL3* missense variants have been identified in two families with congenital heart disease.⁶⁶ Studies showed that homozygous or compound heterozygous *ASXL3* expression caused reduced cell viability, induced cell apoptosis and resulted in abnormal cardiac structure and function in mice.^{66,67} There has been one individual published with compound *ASXL3* missense variants (although these variants were not classified for pathogenicity); this individual had a normal echocardiogram.⁵⁹ Schirwani et al.³⁸ found that nine individuals of the 45-patient cohort, had an echocardiogram for an alternate reason. All of these were reported as normal. Recommendation for routine echocardiography is not described, with the exception of one publication, where an individual with subclavian artery aneurysm and connective-tissue features was described.⁵³

6.2 | Gaps in the literature

In some instances, there was assumption of inheritance given a similar parental phenotype, and in some instances, inheritance status was not discussed (Table A1 in Appendix). De novo status was never given in the absence of confirmatory parental genetic testing. However, inheritance of *ASXL3* variants, from a normal or mildly affected parent, has been reported.⁵³ Therefore, it cannot be presumed that all cases are de novo in the absence of a clinically affected parent.

Similarly, less frequently reported features are also difficult to quantify or associate causality. Details of specific dysmorphology (and other examination findings) were variably reported, and description of dysmorphology can be subjective. Other features, such as hypospadias and naevus flammeus, were rarely reported.

6.3 | Clinical relevance

Confirming the genetic status of the parents of an affected child is important in determining inheritability, and therefore the risk-estimate of a further child with the genetic variant. More accurate data for penetrance is required to attribute disease-recurrence estimates. Even in

the absence of the variant in the blood of parents, there is the small theoretical chance of gonadal mosaicism.

If a pathogenic *ASXL3* variant is identified, there are options for an individual in pregnancy including pre-natal diagnosis (PND) and pre-implantation genetic diagnosis (PGD). There has been one published case of pregnancy termination as a result of significant foetal abnormalities, presenting as pontocerebellar hypoplasia type 1.⁵⁰ A pathogenic *ASXL3* variant was detected on post-mortem whole exome testing.

6.4 | *ASXL3* fly models

The founder and sole member of the *ASXL* family, *Asx* (*Additional sex combs*),¹ was first discovered in fruit flies by Gerd Jurgens.⁶⁸ It was also identified in the ground-breaking *D. melanogaster* screen for developmental genes,⁶⁹ for which Wieschaus and Nusslein-Volhard later received the Nobel Prize ('discoveries concerning the genetic control of early development'), along with Ed Lewis, in 1995. In a series of screens, ethyl methanesulfonate (EMS) was used to induce mutations that perturbed embryonic development, with mutants identified via defects in larval cuticles. This approach enabled the detection of abnormal body patterning phenotypes, for example, segment polarity and denticle morphogenesis (denticles are small bristles that can be seen in cuticle preparation of *Drosophila* larvae). Fly genes are typically named according to phenotype observed when that gene is mutated: correspondingly, *Asx* is named due to the supernumerary sex comb bristles or 'teeth' that enlarge in males.⁶⁸ Sex combs, which are found on the forelegs of male flies, are clusters of thick bristles that male fruit flies use during copulation⁷⁰ and are familiar structures that can be used to determine the sex of *D. melanogaster* when setting up genetic crosses.

Larval cuticle preparations revealed a visible embryonic phenotype characterised as 'head broad, homoeotic, head and thorax partially transformed into abdomen'.⁶⁹ *Asx* was subsequently revealed as a negative regulator of the Bithorax complex,^{71,72} which regulates segment identity in the posterior developing embryo. Once cloned, *Asx* was shown to bind chromatin in regions that overlapped substantially with other polycomb proteins but also at distinct sites.⁷³ Subsequently the PR-DUB complex was defined in flies as consisting of Calypso (BAP1 homologue) and *Asx*, and this complex's deubiquitinating activity is key to balancing H2Aub1 levels and maintaining repression of *HOX* genes and other loci during development.^{27,74}

While *Asx* lacks the N-terminal HARE-HTH domain of vertebrate *ASXL* family members and also contains poly-glutamine and poly-alanine regions unique to the fly gene, the PR-DUB complex plays critical and conserved roles across evolution, though there are differences in regulation of the PRC1 complexes that generate its ubiquitinated substrate.³² Furthermore, the molecular interactions between *Asx* and Calypso have strongly informed our structural understanding of the PR-DUB complex.^{75,76}

While *Asx* is expressed ubiquitously in the fly embryo, specific expression changes are observed within the developing CNS, which may potentially be useful in understanding pathophysiological changes linked to neuronal function (e.g., Reference 69). Model organisms such as *D. melanogaster* are incredibly useful in understanding genetic

mechanisms. Highly genetically tractable with reduced genetic redundancy, yet with a high degree of conservation of key human disease genes, flies are inexpensive, small, have a rapid life cycle, and are amenable to imaging approaches. Their use in research for over 100 years has enabled a generation of functional genetic tools.⁷⁷ With the advent of next generation sequencing of patients, clinical researchers are faced with vast numbers of potentially pathogenic variants in key genes. Flies represent an *in vivo* tool in which the contributions of such allelic variants may be investigated, by coupling the conservation of genes critical to human health with genetic means to introduce human disease gene variants. For example, re-expression of *Asx*—with or without patient-derived polymorphisms—in *Asx* null backgrounds, or direct gene-replacement strategies, enable testing of whether such variants have the potential to be pathogenic, when coupled with observable phenotypes. Such an approach has been taken to study a range of human disease genes, with a particular emphasis on genes involved in neurodevelopmental and neurological conditions^{78,79}; in some cases, the human disease gene is sufficiently related and is able to rescue loss of the *Drosophila* gene's function. Complementary approaches using patient data, human cell-line work and model organisms such as *Drosophila* and zebrafish, have the potential to uncover the underlying mechanisms in disorders such as Bainbridge-Ropers syndrome. There is, therefore, potential to define the pathogenicity of human genetic variants of otherwise uncertain significance.

7 | CONCLUSION

ASXL3-related disorder is a neurodevelopmental disorder caused by pathogenic, or likely pathogenic, heterozygous variants in the ASXL3 gene. To date there have been 108 individuals published in the literature with ASXL3-related neurodevelopmental disorder, in case series or individual case reports. The majority of reported variants are loss-of-function variants in exon 11 and exon 12. Common clinically described features of the condition include feeding difficulties, hypotonia, characteristic facial features, global delay (particularly speech delay), behavioural difficulties and musculoskeletal features.

With increasing patient numbers through our group's ongoing Natural History Study (and ASXL3-registry), in time, we will establish the wide clinical spectrum of the condition, elucidate penetrance data and establish any potential genotype–phenotype correlation (including the role of splice site variants). As there is evidence of inheritability and variability of ASXL3 within families, this will likely unveil a potential mild, and even unaffected, clinical phenotype.

AUTHOR CONTRIBUTIONS

EW: Carried out the literature search, literature analysis and wrote the majority of the article. **NH:** Contributed to the article with molecular insights, including original molecular diagrams and variant formatting. **SA:** Provided expertise and oversight as senior laboratory scientist, and ensured scientific and molecular accuracy. **IR:** Contributed expertise with insights into fly models. **MB:** Supervised the project throughout development and writing.

ACKNOWLEDGEMENTS

I thank all co-authors for their expertise, assistance and help in putting this review article together.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

PEER REVIEW

The peer review history for this article is available at <https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/cge.14506>.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID

Emily Woods  <https://orcid.org/0000-0003-2349-2688>

Iwan R. Evans  <https://orcid.org/0000-0002-3485-4456>

Meena Balasubramanian  <https://orcid.org/0000-0003-1488-3695>

ENDNOTE

¹ N.B., not to be confused with *asx* (*ascutex*), which remains an unmapped genetic locus.

REFERENCES

- Bainbridge MN, Hu H, Muzny DM, et al. De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome. *Genome Med*. 2013;5:11. doi:10.1186/gm415
- Balasubramanian M, Schirwani S. ASXL3-related disorder. In: Adam MP, Everman DB, Mirzaa GM, et al., eds. *GeneReviews [Internet]*. University of Washington; 2020:1993-2023 <https://www.ncbi.nlm.nih.gov/books/NBK563693/>
- Ellard S, Baple EL, Callaway A, et al. ACGS Best Practice Guidelines for Variant Classification in Rare Disease. Available at: 2020 <https://www.acgs.uk.com/media/11631/uk-practice-guidelines-for-variant-classification-v4-01-2020.pdf>
- Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17:405-423. doi:10.1038/gim.2015.30
- Russell B, Johnston JJ, Biesecker LG, et al. Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance. *Am J Med Genet A*. 2015;167A(9):2122-2131. doi:10.1002/ajmg.a.37131
- Shashi V, Pena LD, Kim K, et al. De novo truncating variants in ASXL2 are associated with a unique and recognizable clinical phenotype. *Am J Hum Genet*. 2016;99(4):991-999. doi:10.1016/j.ajhg.2016.08.017
- Katoh M. Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine. *Expert Rev Proteomics*. 2015;12:317-328. doi:10.1586/14789450.2015.1033409
- Katoh M, Katoh M. Identification and characterization of ASXL3 gene in silico. *Int J Oncol*. 2004;24:1617-1622.
- Srivastava A, Ritesh KC, Tsan Y-C, et al. De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in

- Bainbridge-Ropers syndrome. *Hum Mol Genet.* 2016;25:597-608. doi:10.1093/hmg/ddv499
10. Fitzgerald T, Gerety S, Jones W, et al. Large-scale discovery of novel genetic causes of developmental disorders. *Nature.* 2015;519(7542):223-228. doi:10.1038/nature14135
 11. The 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature.* 2015;526:68-74. doi:10.1038/nature15393
 12. Wright CF, Fitzgerald TW, Jones WD, et al. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. *Lancet.* 2015;385:1305-1314. doi:10.1016/S0140-6736(14)61705-0
 13. Chinen Y, Nakamura S, Ganaha A, et al. Mild prominence of the Sylvian fissure in a Bainbridge-Ropers syndrome patient with a novel frameshift variant in ASXL3. *Clin Case Rep.* 2018;6:330-336. doi:10.1002/ccr3.1361
 14. Contreras-Capetillo SN, Vilchis-Zapata ZH, Ribbón-Conde J, Pinto-Escalante D. Global developmental delay and postnatal microcephaly: Bainbridge-Ropers syndrome with a new mutation in ASXL3. *Neurología (English Edition).* 2018;33:484-486. doi:10.1016/j.nrleng.2017.01.005
 15. Dinwiddie DL, Soden SE, Saunders CJ, et al. De novo frameshift mutation in ASXL3 in a patient with global developmental delay, microcephaly, and craniofacial anomalies. *BMC Med Genet.* 2013;6:32. doi:10.1186/1755-8794-6-32
 16. Hori I, Miya F, Ohashi K, et al. Novel splicing mutation in the ASXL3 gene causing Bainbridge-Ropers syndrome. *Am J Med Genet.* 2016;170:1863-1867. doi:10.1002/ajmg.a.37653
 17. Wang Q, Zhang J, Jiang N, Xie J, Yang J, Zhao X. De novo nonsense variant in ASXL3 in a Chinese girl causing Bainbridge-Ropers syndrome: a case report and review of literature. *Mol Gen Gen Med.* 2022;10:e1924. doi:10.1002/mgg3.1924
 18. Wu K, Cong Y. Case report: a novel ASXL3 gene variant in a Sudanese boy. *BMC Pediatr.* 2021;21:557. doi:10.1186/s12887-021-03038-8
 19. Yang L, Guo B, Zhu W, et al. Bainbridge-ropers syndrome caused by loss-of-function variants in ASXL3: clinical abnormalities, medical imaging features, and gene variation in infancy of case report. *BMC Pediatr.* 2020;20:287. doi:10.1186/s12887-020-02027-7
 20. De Ayala Alonso AG, Gutiérrez L, Fritsch C, Papp B, Beuchle D, Müller J. A genetic screen identifies novel polycomb group genes in *Drosophila*. *Genetics.* 2007;176(4):2099-2108. doi:10.1534/genetics.107.075739
 21. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. *Nucleic Acids Res.* 2000;28(1):235-242. doi:10.1093/nar/28.1.235
 22. Varadi M, Anyango S, Deshpande M, et al. AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. *Nucleic Acids Res.* 2022;50(D1):D439-D444. doi:10.1093/nar/gkab1061
 23. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. *Nature.* 2021;596(7873):583-589. doi:10.1038/s41586-021-03819-2
 24. Katoh M. Functional and cancer genomics of ASXL family members. *Br J Cancer.* 2013;109(2):299-306. doi:10.1038/bjc.2013.281
 25. Sanchez-Pulido L, Kong L, Ponting CP. A common ancestry for BAP1 and Uch37 regulators. *Bioinformatics.* 2012;28(15):1953-1956. doi:10.1093/bioinformatics/bts319
 26. Aravind L, Iyer LM. The HARE-HTH and associated domains. *Cell Cycle.* 2012;11(1):119-31.
 27. Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB. *Nature.* 2010;465(7295):243-247. doi:10.1038/nature08966
 28. Zhang J, Pei J, Durham J, Bos T, Cong Q. Computed cancer interactome explains the effects of somatic mutations in cancers. *Protein Sci.* 2022;31(12):e4479. doi:10.1002/pro.4479
 29. Sanchez R, Zhou MM. The PHD finger: a versatile epigenome reader. *Trends Biochem Sci.* 2011;36(7):364-372. doi:10.1016/j.tibs.2011.03.005
 30. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 2019;47(D1):D607-D613. doi:10.1093/nar/gky1131
 31. Kolovos P, Nishimura K, Sankar A, et al. PR-DUB maintains the expression of critical genes through FOXK1/2-and ASXL1/2/3-dependent recruitment to chromatin and H2AK119ub1 deubiquitination. *Genome Res.* 2020;30(8):1119-1130. doi:10.1101/gr.261016.120
 32. Reddington CJ, Fellner M, Burgess AE, Mace PD. Molecular regulation of the polycomb repressive-deubiquitinase. *Int J Mol Sci.* 2020;21(21):7837. doi:10.3390/ijms21217837
 33. Daou S, Hammond-Martel I, Mashtalir N, et al. The BAP1/ASXL2 histone H2A deubiquitinase complex regulates cell proliferation and is disrupted in cancer. *J Biol Chem.* 2015;290(48):28643-28663. doi:10.1074/jbc.M115.661553
 34. Sahtoe DD, Van Dijk WJ, Ekkebus R, Ovaa H, Sixma TK. BAP1/ASXL1 recruitment and activation for H2A deubiquitination. *Nat Commun.* 2016;7(1):10292. doi:10.1038/ncomms10292
 35. Szczepanski AP, Zhao Z, Sosnowski T, Goo YA, Bartom ET, Wang L. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer. *Genome Med.* 2020;12(1):1-20. doi:10.1186/s13073-020-00760-3
 36. Chiang CM. Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4. *F1000 Biol Rep.* 2009;1. doi:10.3410/B1-98
 37. Ikekwe JC, Osuagwu FC, LePlatte D, Ghaziuddin M. Comorbid psychiatric aspects of Bainbridge-Ropers syndrome. *Prim Care Companion CNS Disord.* 2021;23:34115. doi:10.4088/PCC.20m02783
 38. Schirwani S, Albaba S, Carere DA, et al. Expanding the phenotype of ASXL3-related syndrome: a comprehensive description of 45 unpublished individuals with inherited and de novo pathogenic variants in ASXL3. *Am J Med Genet A.* 2021;185:3446-3458. doi:10.1002/ajmg.a.62465
 39. Balasubramanian M, Willoughby J, Fry AE, et al. Delineating the phenotypic spectrum of Bainbridge-Ropers syndrome: 12 new patients with de novo, heterozygous, loss-of-function mutations in ASXL3 and review of published literature. *J Med Genet.* 2017;54:537-543. doi:10.1136/jmedgenet-2016-104360
 40. Dad R, Walker S, Scherer SW, Hassan MJ, Kang SY, Minassian BA. Hyperventilation-athetosis in ASXL3 deficiency (Bainbridge-Ropers) syndrome. *NeuroGenet.* 2017;3:e189. doi:10.1212/NXG.0000000000000189
 41. Qiao L, Liu Y, Ge J, Li T. Novel nonsense mutation in ASXL3 causing Bainbridge-Ropers syndrome. *Indian Pediatr.* 2019;56:792-794. doi:10.1007/s13312-019-1627-y
 42. Li J-R, Huang Z, Lu Y, Ji Q-Y, Jiang M-Y, Yang F. Novel mutation in the ASXL3 gene in a Chinese boy with microcephaly and speech impairment: a case report. *WJCC.* 2020;8:6465-6472. doi:10.12998/wjcc.v8.i24.6465
 43. Cuddapah VA, Dubbs HA, Adang L, et al. Understanding the phenotypic spectrum of ASXL-related disease: ten cases and a review of the literature. *Am J Med Genet A.* 2021;185:1700-1711. doi:10.1002/ajmg.a.62156
 44. Koboldt DC, Mihalic Mosher T, Kelly BJ, et al. A de novo nonsense mutation in ASXL3 shared by siblings with Bainbridge-Ropers syndrome. *Cold Spring Harb Mol Case Stud.* 2018;4:a002410. doi:10.1101/mcs.a002410
 45. Kuechler A, Czeschik JC, Graf E, et al. Bainbridge-Ropers syndrome caused by loss-of-function variants in ASXL3: a recognizable condition. *Eur J Hum Genet.* 2017;25:183-191. doi:10.1038/ejhg.2016.165
 46. Wayhelova M, Oppelt J, Smetana J, et al. Novel de novo frameshift variant in the ASXL3 gene in a child with microcephaly and global developmental delay. *Mol Med Rep.* 2019;20:505-512. doi:10.3892/mmr.2019.10303

47. Khan TR, Dolce A, Goodspeed K. A case of Bainbridge-Ropers syndrome with breath holding spells and intractable epilepsy: challenges in diagnosis and management. *BMC Neurol.* 2022;22:60. doi:10.1186/s12883-022-02573-w
48. Myers KA, White SM, Mohammed S, et al. Childhood-onset generalized epilepsy in Bainbridge-Ropers syndrome. *Epilepsy Res.* 2018;140:166-170. doi:10.1016/j.eplepsyres.2018.01.014
49. Yu KP-T, Luk H-M, Fung JLF, Chung BH-Y, Lo IF-M. Further expanding the clinical phenotype in Bainbridge-Ropers syndrome and dissecting genotype-phenotype correlation in the ASXL3 mutational cluster regions. *Eur J Med Genet.* 2021;64:104107. doi:10.1016/j.ejmg.2020.104107
50. Bacrot S, Mechler C, Talhi N, et al. Whole exome sequencing diagnoses the first fetal case of Bainbridge-Ropers syndrome presenting as pontocerebellar hypoplasia type 1. *Birth Defects Res.* 2018;110:538-542. doi:10.1002/bdr2.1191
51. Schirwani S, Hauser N, Platt A, et al. Mosaicism in ASXL3-related syndrome: description of five patients from three families. *Eur J Med Genet.* 2020;63:103925. doi:10.1016/j.ejmg.2020.103925
52. Laquerriere A, Jaber D, Abiusi E, et al. Phenotypic spectrum and genomics of undiagnosed arthrogyrosis multiplex congenita. *J Med Genet.* 2022;59:559-567. doi:10.1136/jmedgenet-2020-107595
53. Schirwani S, Woods E, Koolen DA, et al. Familial Bainbridge-Ropers syndrome: report of familial ASXL3 inheritance and a milder phenotype. *Am J Med Genet A.* 2023;191:29-36. doi:10.1002/ajmg.a.62981
54. Verhoeven W, Egger J, Räkens E, van Erkelens A, Pfundt R, Willemsen M. Phenotypic characterization of an older adult male with late-onset epilepsy and a novel mutation in ASXL3 shows overlap with the associated Bainbridge-Ropers syndrome. 2018;14:867-870. doi:10.2147/NDT.S153511
55. Awamleh Z, Chater-Diehl E, Choufani S, et al. DNA methylation signature associated with Bohring-Opitz syndrome: a new tool for functional classification of variants in ASXL genes. *Eur J Hum Genet.* 2022;30:695-702. doi:10.1038/s41431-022-01083-0
56. De Rubeis S, He X, Goldberg AP, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature.* 2014;515:209-215. doi:10.1038/nature13772
57. Karaca E, Harel T, Pehlivan D, et al. Genes that affect brain structure and function identified by rare variant analyses of Mendelian neurologic disease. *Neuron.* 2015;88:499-513. doi:10.1016/j.neuron.2015.09.048
58. Alfares A, Alfadhel M, Wani T, et al. The HARE-HTH and associated domains: novel modules in the coordination of epigenetic DNA and protein modifications. *Cell Cycle.* 2012;11(1):119-131. doi:10.4161/cc.11.1.18475
59. Giri D, Rigden D, Didi M, Peak M, McNamara P, Senniappan S. Novel compound heterozygous ASXL3 mutation causing Bainbridge-ropers like syndrome and primary IGF1 deficiency. *Int J Pediatr Endocrinol.* 2017;2017:8. doi:10.1186/s13633-017-0047-9
60. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature.* 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7
61. Firth HV, Richards SM, Bevan AP, et al. DECIPHER: database of chromosomal imbalance and phenotype in humans using ensembl resources. *Am J Hum Genet.* 2009;84(4):524-533. doi:10.1016/j.ajhg.2009.03.010
62. Wright CF, Prigmore E, Rajan D, et al. Clinically-relevant postzygotic mosaicism in parents and children with developmental disorders in trio exome sequencing data. *Nat Commun.* 2019;10:2985. doi:10.1038/s41467-019-11059-2
63. Lichtig H, Artamonov A, Polevoy H, Reid CD, Bielas SL, Frank D. Modeling Bainbridge-Ropers syndrome in *Xenopus laevis* embryos. *Front Physiol.* 2020;11:75. doi:10.3389/fphys.2020.00075
64. Zhang S, Fu F, Zhen L, Li R, Liao C. Alteration of long non-coding RNAs and mRNAs expression profiles by compound heterozygous ASXL3 mutations in the mouse brain. *Bioengineered.* 2021;12:6935-6951. doi:10.1080/21655979.2021.1974811
65. Slatnick LR, Angione K, Hartman L. Precursor B-cell acute lymphoblastic leukemia in a pediatric patient with Bainbridge-Ropers syndrome. *Pediatr Blood Cancer.* 2023;70:e29873. doi:10.1002/pbc.29873
66. Fu F, Li R, Lei T-Y, et al. Compound heterozygous mutation of the ASXL3 gene causes autosomal recessive congenital heart disease. *Hum Genet.* 2021;140:333-348. doi:10.1007/s00439-020-02200-z
67. Liu Z-Q, Cheng M, Fu F, et al. Identification of differential microRNAs and messenger RNAs resulting from ASXL transcriptional regulator 3 knockdowns during heart development. *Bioengineered.* 2022;13:9948-9961. doi:10.1080/21655979.2022.2062525
68. Lindsley DL, Zimm GG. *The Genome of Drosophila Melanogaster.* Academic Press; 1992.
69. Nüsslein-Volhard C, Wieschaus E, Kluding H. Mutations affecting the pattern of the larval cuticle in *Drosophila melanogaster*: I. Zygotic loci on the second chromosome. *Wilhelm Roux's Arch Dev Biol.* 1984;193(5):267-282. doi:10.1007/BF00848156
70. Ng CS, Kopp A. Sex combs are important for male mating success in *Drosophila melanogaster.* *Behav Genet.* 2008;38(2):195-201. doi:10.1007/s10519-008-9190-7
71. Breen TR, Duncan IM. Maternal expression of genes that regulate the bithorax complex of *Drosophila melanogaster.* *Dev Biol.* 1986;118(2):442-456. doi:10.1016/0012-1606(86)90015-1
72. Jürgens G. A group of genes controlling the spatial expression of the bithorax complex in *Drosophila.* *Nature.* 1985;316:153-155. doi:10.1038/316153a0
73. Sinclair DA, Milne TA, Hodgson JW, et al. The additional sex combs gene of *Drosophila* encodes a chromatin protein that binds to shared and unique polycomb group sites on polytene chromosomes. *Development.* 1998;125(7):1207-1216. doi:10.1242/dev.125.7.1207
74. Bonnet J, Boichenko I, Kalb R, et al. PR-DUB preserves polycomb repression by preventing excessive accumulation of H2Aub1, an antagonist of chromatin compaction. *Genes Dev.* 2022;36(19-20):1046-1061. doi:10.1101/gad.350014.122
75. De I, Chittock EC, Grötsch H, Miller TCR, McCarthy AA, Müller CW. Structural basis for the activation of the deubiquitinase calypso by the polycomb protein ASX. *Structure (London, England: 1993).* 2019;27(3):528-536. doi:10.1016/j.str.2018.11.013
76. Foglizzo M, Middleton AJ, Burgess AE, et al. A bidentate polycomb repressive-deubiquitinase complex is required for efficient activity on nucleosomes. *Nat Commun.* 2018;9(1):3932. doi:10.1038/s41467-018-06186-1
77. Hales KG, Korey CA, Larracuent AM, Roberts DM. Genetics on the fly: a primer on the *Drosophila* model system. *Genetics.* 2015;201(3):815-842. doi:10.1534/genetics.115.183392
78. Bellen HJ, Wangler MF, Yamamoto S. The fruit fly at the interface of diagnosis and pathogenic mechanisms of rare and common human diseases. *Hum Mol Genet.* 2019;28(R2):R207-R214. doi:10.1093/hmg/ddz135
79. Link N, Bellen HJ. Using *Drosophila* to drive the diagnosis and understand the mechanisms of rare human diseases. *Development.* 2020;147(21):dev191411. doi:10.1242/dev.191411

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Woods E, Holmes N, Albaba S, Evans IR, Balasubramanian M. ASXL3-related disorder: Molecular phenotyping and comprehensive review providing insights into disease mechanism. *Clinical Genetics.* 2024;1-18. doi:10.1111/cge.14506

APPENDIX

TABLE A1 Variants in the literature.

Source/Reference	Patient	Decipher	Variant	Exon	Inheritance	ACMG criteria	Classification	Effect
Schirwani et al. ³⁸	1	258 284	c.4479_4483del p.(Ser1493fs)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸ Schirwani et al. ⁵³	2	286 691	c.4534C>T p.(Gln1512*)	12	Maternal*	PVS1_str, PM2, PS2_mod, PS4_sup	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	3	300 784	c.2066del p.(Ile689fs)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Schirwani et al. ³⁸	4	362 009	c.1534_1535del p.(Leu512fs)	11	De novo	PVS1, PM2, PS2_mod, PS4_sup	Pathogenic	NMD likely
Schirwani et al. ³⁸	5	307 301	c.5659A>T p.(Arg1887*)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	6	305 747	c.3811_3814dup p.(Thr1272fs)	12	De novo	PVS1_str, PM2	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	7	275 275	c.1606C>T p.(Gln536*)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Schirwani et al. ³⁸	8	274 520	c.1921_1924dup p.(Pro642fs)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Schirwani et al. ³⁸	9	286 921	c.4330C>T p.(Arg1444*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_mod	Pathogenic	>10% protein lost
Schirwani et al. ³⁸ Schirwani et al. ⁵³	10	/	c.2791_2792del p.(Gln931fs)	11	Paternal*	PVS1, PM2	Likely pathogenic	NMD likely
Schirwani et al. ³⁸	11	/	c.2791_2792del p.(Gln931fs)	11	Unknown	PVS1, PM2	Likely pathogenic	NMD likely
Schirwani et al. ³⁸	12	/	c.3382del p.(Arg1128fs)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	13	/	c.1095_1096del p.(Glu367fs)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Schirwani et al. ³⁸	14	/	c.1884_1885del p.(Gly629fs)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Schirwani et al. ³⁸	15	/	c.55_879del p.(Ala19_Gln293del)	2 to 8	De novo	PM4, PM2, PS2_mod	Likely pathogenic	Arr[hg19] 18q12.1 (31172484_31311379)x1 dn. Size of intragenic deletion is 139 kb
Schirwani et al. ³⁸	16	/	c.1534_1535del p.(Leu512fs)	11	De novo	PVS1, PM2, PS2_mod, PS4_sup	Pathogenic	NMD likely
Schirwani et al. ³⁸	17	/	c.1579dup p.(Gln527fs)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely

(Continues)

TABLE A1 (Continued)

Source/ Reference	Patient	Decipher	Variant	Exon	Inheritance	ACMG criteria	Classification	Effect
Schirwani et al. ³⁸	18	/	c.4894_4895del p.(Glu1632fs)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	19	/	c.1451_1454del p.(Thr484fs)	11	De novo	PVS1, PM2	Likely pathogenic	NMD likely
Schirwani et al. ³⁸	20	/	c.1990C>T p.(Gln664*)	11	De novo	PVS1, PM2, PS2_mod, PS4_sup	Pathogenic	NMD likely
Schirwani et al. ³⁸	21	/	c.1698_1699del p.(Glu566fs)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Schirwani et al. ³⁸ Schirwani et al. ⁵³	22	/	c.4441dup p.(Leu1481fs)	12	Maternal	PVS1_str, PM2	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	23	/	c.4462_4465del p.(Thr1488fs)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	24	/	c.1579dup p.(Gln527fs)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Schirwani et al. ³⁸	25	/	c.1535T>A p.(Leu512*)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Schirwani et al. ³⁸	26	/	c.4399C>T p.(Arg1467*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_mod	Pathogenic	>10% protein lost
Schirwani et al. ³⁸	27	/	c.4399C>T p.(Arg1467*)	12	Unknown	PVS1_str, PM2, PS2_mod, PS4_mod	Pathogenic	>10% protein lost
Schirwani et al. ³⁸	28	/	c.1783C>T p.(Gln595*)	11	De novo	PVS1, PM2, PS2_mod, PS4_sup	Pathogenic	NMD likely
Schirwani et al. ³⁸	29	/	c.4871_4874del p.(His1624fs)	12	De novo	PVS1_str, PM2	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	30	/	c.3178dup p.(Arg1060fs)	12	De novo	PVS1_str, PM2, PS4_sup, PS2_mod	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	31	/	c.4330C>T p.(Arg1444*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_mod	Pathogenic	>10% protein lost
Schirwani et al. ³⁸	32	/	c.1500del p.(Glu500fs)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Schirwani et al. ³⁸	33	/	c.3464C>A p.(Ser1155*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_sup	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	34	262 694	c.3106C>T p.(Arg1036*)	12	Unknown	PVS1_str, PM2, PS2_mod, PS4_mod	Pathogenic	>10% protein lost
Schirwani et al. ³⁸	35	/	c.4360C>T p.(Gln1454*)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost

TABLE A1 (Continued)

Source/ Reference	Patient	Decipher	Variant	Exon	Inheritance	ACMG criteria	Classification	Effect
Schirwani et al. ³⁸	36	/	c.4399C>T p.(Arg1467*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_mod	Pathogenic	>10% protein lost
Schirwani et al. ³⁸	37	305 643	c.4534C>T p.(Gln1512*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_sup	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	38	/	c.1505_1508dup p.(Met504fs)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Schirwani et al. ³⁸	39	/	c.4219_4220del p.(Leu1407fs)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	40	/	c.4120_4123dup p.(Ala1375fs)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	41	/	c.4336_4337del p.(Arg1446fs)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	42	274 637	c.3419del p.(Pro1140fs)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Schirwani et al. ³⁸	43	264 183	c.1406_1409dup p.(His470fs)	11	De novo	PVS1, PM2	Pathogenic	NMD likely
Schirwani et al. ³⁸	44	263 416	c.4330C>T p.(Arg1444*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_mod	Pathogenic	>10% protein lost
Schirwani et al. ³⁸	45	/	c.187C>T p.(Arg63*)	3	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Balasubramanian et al. ³⁹	46	274 629	c.4330C>T p.(Arg1444*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_mod	Pathogenic	>10% protein lost
Balasubramanian et al. ³⁹	47	275 029	c.1201del p.(Ala401fs)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Balasubramanian et al. ³⁹	48	274 593	c.1074T>A p.(Tyr358*)	10	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Balasubramanian et al. ³⁹	49	278 695	c.4144C>T p.(Gln1382*)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Balasubramanian et al. ³⁹	50	261 513	c.1783C>T p.(Gln595*)	11	De novo	PVS1, PM2, PS2_mod, PS4_sup	Pathogenic	NMD likely
Balasubramanian et al. ³⁹	51	265 854	c.3355dup p.(His1119fs)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Balasubramanian et al. ³⁹	52	271 912	c.1082dup p.(Leu362fs)	10	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Balasubramanian et al. ³⁹	53	275 860	c.3635T>G p.(Leu1212*)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost

(Continues)

TABLE A1 (Continued)

Source/ Reference	Patient	Decipher	Variant	Exon	Inheritance	ACMG criteria	Classification	Effect
Balasubramanian et al. ³⁹	54	265 908	c.3127_3128dup p.(Gly1045fs)	12	De novo	PVS1_str, PM2, PS2_mod	Pathogenic	>10% protein lost
Balasubramanian et al. ³⁹	55	259 240	c.3178dup p.(Arg1060fs)	12	De novo	PVS1_str, PM2, PS4_sup, PS2_mod	Likely pathogenic	>10% protein lost
Balasubramanian et al. ³⁹	56	272 591	c.1485_1488dup, p.(Asp497*)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Balasubramanian et al. ³⁹	57	208 772	c.1491dup p.(Asn498*)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Wang et al. ¹⁷	58	/	c.1063G>T (p.Glu355*)	10	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Wu and Cong ¹⁸	59	/	c.3043C>T p.(Gln1015*)	12	De novo	PVS1, PM2, PS2_mod	Pathogenic	>10% protein lost
Srivastava et al. ⁹	60	/	c.4330C>T p.(Arg1444*)	12	Unknown	PVS1_str, PM2, PS2_mod, PS4_mod	Pathogenic	>10% protein lost
Srivastava et al. ⁹	61	/	c.3364C>T p.(Gln1122*)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Srivastava et al. ⁹	62	/	c.1448dup p.(Thr484fs)	11	De novo	PVS1, PM2	Pathogenic	NMD likely
Dad et al. ⁴⁰	63	/	c.1314_1316delinsA p.(Ser439fs)	11	De novo	PVS1, PM2	Pathogenic	NMD likely
Qiao et al. ⁴¹	64	/	c.3464C>A p.(Ser1155*)	12	De novo	PVS1_str, PM2, PS2_mod, PS2_sup	Likely pathogenic	>10% of protein lost
Li et al. ⁴²	65	/	c.1795G>T p.(Glu599*)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Yang et al. ¹⁹	66	/	c.3494_3495del p.(Cys1165*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_sup	Pathogenic	>10% of protein lost
Giri et al. ⁵⁹	67	/	c.2965C>G, p.(Arg989Gly) and c.3078G>C, p.(Lys1026Asn)	11 and 12	Maternal and paternal	c.2965C>G BS1, BS2, BP1, BP4 c.3078G>C BP1, BP4	c.2965C>G Benign c.3078G>C Likely benign	-
Cuddapah et al. ⁴³	68	/	c.4322C>G p.(Ser1441*)	12	De novo	PVS1_str, PM2	Likely pathogenic	>10% protein lost
Cuddapah et al. ⁴³	69	/	c.1895dup p.(Gln633fs)	11	De novo	PVS1, PM2	Pathogenic	NMD likely
Cuddapah et al. ⁴³	70	/	c.3349C>T p.(Arg1117*)	12	De novo	PVS1_str, PM2	Likely pathogenic	>10% protein lost
Cuddapah et al. ⁴³	71	/	c.1990C>T p.(Gln664*)	11	De novo	PVS1, PM2, PS2_mod, PS4_sup	Pathogenic	NMD likely
Bainbridge et al. ¹	72	/	c.1210C>T p.(Gln404*)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely

TABLE A1 (Continued)

Source/ Reference	Patient	Decipher	Variant	Exon	Inheritance	ACMG criteria	Classification	Effect
Bainbridge et al. ¹	73	/	c.1396C>T p.(Gln466*)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Bainbridge et al. ¹	74	/	c.1422dup p.(Glu475*)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Bainbridge et al. ¹	75	/	c.1978_1981del p.(Asp660fs)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Koboldt et al. ⁴⁴	76	/	c.3106C>T, p.(Arg1036*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_mod	Pathogenic	>10% of protein lost
Koboldt et al. ⁴⁴	77	/	c.3106C>T, p.(Arg1036*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_mod	Pathogenic	>10% of protein lost
Kuechler et al. ⁴⁵	78	327 923	c.1219del p.(Ser407fs)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Kuechler et al. ⁴⁵	79	327 924	c.1369G>T p.(Glu457*)	11	De novo	PVS1, PM2	Pathogenic	NMD likely
Kuechler et al. ⁴⁵	80	327 925	c.3106C>T p.(Arg1036*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_mod	Pathogenic	>10% protein lost
Kuechler et al. ⁴⁵	81	327 926	c.3494_3495del p.(Cys1165*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_sup	Pathogenic	>10% protein lost
Kuechler et al. ⁴⁵	82	327 927	c.3613G>T p.(Glu1205*)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Kuechler et al. ⁴⁵	83	327 928	c.4072_4073del p.(Val1358fs)	12	De novo	PVS1_str, PM2	Likely pathogenic	>10% protein lost
Chinen et al. ¹³	84	/	c.3032del p.(Pro1011fs)	11	De novo	PVS1_str, PM2	Likely pathogenic	>10% protein lost
Contreras- Capetillo et al. ¹⁴	85	/	c.2992_2995del p.(Glu998fs)	11	De novo	PVS1_str, PM2	Likely pathogenic	>10% protein lost
Dinwiddie et al. ¹⁵	86	/	c.1897_1898del p.(Gln633fs)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Wayhelova et al. ⁴⁶	87	/	c.3006del p.(Arg1004fs)	11	De novo	PVS1_str, PM2	Likely pathogenic	>10% protein lost
Verhoeven et al. ⁵⁴	88	/	c.6697_6710dup p.(Ser2238fs)	12	Unknown	PVS1_mod, PM2	Variant of unknown significance	<10% of protein lost
Khan et al. ⁴⁷	89	/	c.1612G>T, p.(Glu538*)	11	De novo	PVS1, PM2	Pathogenic	NMD likely
Myers et al. ⁴⁸	90	/	c.3106C>T p.(Arg1036*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_mod	Pathogenic	>10% protein lost

(Continues)

TABLE A1 (Continued)

Source/ Reference	Patient	Decipher	Variant	Exon	Inheritance	ACMG criteria	Classification	Effect
Myers et al. ⁴⁸	91	271 709	c.3039+1G>A	Splice site	De novo	PVS1_str, PM2, PS2_mod, PS4_sup	Likely pathogenic	Predicted skipping of exon 11 >10% protein lost
Myers et al. ⁴⁸	92	295 117	c.3315_3318del p.(Thr1106fs)	12	De novo	PVS1_str, PM2	Likely pathogenic	>10% protein lost
Yu et al. ⁴⁹	93	421 415	c.3307A>T p.(Lys1103*)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Yu et al. ⁴⁹	94	421 418	c.5455C>T p.(Gln1819*)	12	De novo	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Yu et al. ⁴⁹	95	421 420	c.1377_1378del p.(Glu459fs*)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Yu et al. ⁴⁹	96	/	c.4399C>T p.(Arg1467*)	12	De novo	PVS1_str, PM2, PS2_mod, PS4_mod	Pathogenic	>10% protein lost
Hori et al. ¹⁶	97	/	c.3039+1G>A	Splice site	De novo	PVS1_str, PM2, PS2_mod, PS4_sup	Likely pathogenic	Predicted skipping of exon 11 >10% protein lost
Bacrot et al. ⁵⁰	98	/	c.1318dup p.(Glu440fs)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Schirwani et al. ⁵¹	99	292 512	c.3287_3291del p.(Thr1096fs)	12	De novo (likely parent mosaic)	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Schirwani et al. ⁵¹	100	292 513	c.3287_3291del p.(Thr1096fs)	12	De novo (likely parent mosaic)	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Schirwani et al. ⁵¹	101	/	c.4509_4513dup p.(Val1505fs)	12	De novo (likely parent mosaic)	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Schirwani et al. ⁵¹	102	/	c.4509_4513dup p.(Val1505fs)	12	De novo (likely parent mosaic)	PVS1_str, PM2, PS2_mod	Likely pathogenic	>10% protein lost
Schirwani et al. ⁵¹	103	/	c.1632_1637delins31 p.(Pro545fs) (mosaic)	11	De novo	PVS1, PM2, PS2_mod	Pathogenic	NMD likely
Ikekwe et al. ³⁷	Possible 104–110	/	No variant data provided Unable to determine if otherwise previously reported	/	/	/	/	/

Note: De novo—confirmed with parental genetic testing. ACMG Criterion applied: PS2_mod: De novo (both maternity and paternity confirmed) in a patient with the disease and no family history, used at moderate level since the phenotype in our cohort of patients was consistent but not highly specific to the ASXL3 gene. PVS1: null variant (nonsense, frameshift, canonical ± 1 or 2 splice sites, initiation codon, single or multiexon deletion) in a gene where LOF is a known mechanism of disease, used at very strong level. We downgraded this evidence too strong for truncating variants within the last exon but predicted to result in >10% loss of protein size (PVS1_str) or <10% loss of protein size (PVS1_mod). PM2: Absent from controls in gnomAD database, used at moderate level. PM4: Protein length changes as a result of in-frame deletions/insertions in a nonrepeat region or stop-loss variants, used at moderate level. PS4_sup: Variant previously identified in one unrelated individual and not seen in gnomAD. PS4_mod: Variant previously identified in two or more unrelated individuals.

*Presumed inheritance due to parental phenotype consistent with ASXL3-related disorder.